BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...mAb targeting the NK cell activating receptor NKG2D...
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...the only investor in a series A round. MICA is an activating ligand for the NKG2D...
...Approach” ). Targets MICA - MHC class I polypeptide-related sequence A NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1 Lauren...
...Killer cell lectin-like receptor subfamily K member 1 Lauren Martz, Senior Editor Cullinan Oncology LLC PDI Therapeutics Inc. Avalon Ventures MHC class I polypeptide-related sequence A (MICA) Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...IL-13) receptor alpha 2 (IL-13RA2) (IL-13R) (CD213A2) Melanoma-associated antigen A4 (MAGEA4) Mesothelin Mucin 1 (MUC1) (CD227) Mucin 16 (MUC16) (CA125) Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314) Prostate...
BioCentury | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

...report additional data from the trial in 1H20. CYAD-101 is an allogeneic CAR T targeting NKG2D...
...Targets: IL2RB (CD122) - Interleukin-2 receptor β chain; IL-15 - Interleukin-15; NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1...
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BioCentury | Sep 4, 2019
Finance

Nkarta’s $114M series B to fund clinical NK cell programs, manufacturing facility

...cell therapy genetically modified to express a chimeric NKG2D receptor complex and a membrane-bound IL-15. NKG2D...
...Fcγ receptor III; IL-15 - Interleukin-15; NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1 Lauren Martz, Associate Editor Nkarta Inc. Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)...
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

...from causing graft-versus host disease (GvHD). In the other, it uses shRNA to prevent its NKG2D-based...
...a next-generation version of its NKG2D-based CAR that used shRNA knockdown to reduce expression of NKG2D...
...chemokine receptor 5 CD3ζ (CD247) miR-30 - MicroRNA-30 miR-196a - MicroRNA-196a NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...University of Pennsylvania / Novartis AG (NYSE:NVS; SIX:NOVN) CAR-EGFR/EGFRvIII-T Glioma Ph I/II Killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314...
Items per page:
1 - 10 of 81